RxDoctor Payments Data

Margaret Fitzsimmons, MD

Family Medicine · Fortville, INNPI 1689617672

Payments from drug & device makers

$1,104in general payments, 2019–2025

Across 58 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$247
  • Novo Nordisk$181
  • Lilly USA, LLC$127
  • Astellas Pharma US Inc$94
  • Amgen$72
  • Axsome Therapeutics, Inc.$58
  • plus $325 from 10 others

What the payments were for

  • Food & beverage$1,104100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,104 in reported general payments places this provider in the 60th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$80,109
Medicare patients
172
Services billed
1,178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab48$48,827
MounjaroTirzepatide45$46,715
JanuviaSitagliptin Phosphate38$42,801
EliquisApixaban30$34,628
FarxigaDapagliflozin Propanediol29$32,337
AbrysvoRsv Vacc, Pref A And Pref B/Pf101$32,099
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$30,963
Breo ElliptaFluticasone/Vilanterol54$27,440
XareltoRivaroxaban25$22,470
JardianceEmpagliflozin13$20,907
TrulicityDulaglutide20$20,300
RybelsusSemaglutide19$15,807
OzempicSemaglutide13$12,344
ShingrixVaricella-Zoster Ge/As01b/Pf41$9,040
MyrbetriqMirabegron14$7,400

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$51$67,443130 claims
Lilly USA, LLCMounjaro, Trulicity$127$67,01465 claims
PfizerEliquis, Abrysvo$33$66,727131 claims
AstraZenecaFarxiga$48$32,33729 claims
Novo NordiskRybelsus, Ozempic$181$28,15132 claims
Astellas Pharma US IncMyrbetriq$94$7,40014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Fortville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →